Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Nanomedicine and Addictive Disorders: A New Approach With Cannabinoids

Author(s): Virna Margarita Martín Giménez, Sebastián García Menéndez and Walter Manucha*

Volume 28, Issue 34, 2022

Published on: 19 September, 2022

Page: [2795 - 2799] Pages: 5

DOI: 10.2174/1381612828666220907104354

Price: $65

Abstract

Background: Most cannabinoids usually present several limitations when evaluating their clinical use, mainly related to the side effects they may cause at the central nervous system and other levels. In this regard, nanotechnology applied to the development of pharmacotherapeutic nanoformulations has become an attractive tool that allows taking advantage of the beneficial properties of multiple drugs while minimizing or avoiding their undesirable side effects. Nanotechnology is a relatively recent scientific field that involves the study, manipulation, development, and characterization of drug delivery systems at the nanoscale (1 to 1000 nm; 1 nm= 1x10-9 m). Usually, the physicochemical properties of matter at the nanoscale are significantly different compared to the matter at the macroscale, which provides several advantages over conventional therapeutic alternative types of organic and inorganic drug delivery nanosystems. Posology, size, composition, surface properties, and different physicochemical characteristics may directly or indirectly influence their pharmacodynamic and pharmacokinetic behavior and, consequently, their biomedical use.

Purpose of Review: This mini-review summarizes the main recent findings on nanomedical strategies and applications for cannabinoid encapsulation, raising the possibility of transferring these advances to the therapy of addictions.

Highlights Standpoints: The nano therapy significantly improves the pharmacokinetic and pharmacodynamic behavior of multiple active pharmaceutical ingredients with different limitations and disadvantages, thus enhancing the therapeutic compliance of patients. In general, cannabinoids loaded in nanoformulations offer greater efficacy, lower toxicity and more controlled/prolonged release than cannabinoids in free form.

Keywords: Addictions, phytocannabinoids, synthetic cannabinoids, endocannabinoids, nanotechnology, therapeutic molecules.

« Previous Next »
[1]
Suzuki J, Weiss RD. Cannabinoids for the treatment of opioid use disorder: Where is the evidence? J Addict Med 2021; 15(2): 91-2.
[http://dx.doi.org/10.1097/ADM.0000000000000711] [PMID: 32909980]
[2]
Nance E. Careers in nanomedicine and drug delivery. Adv Drug Deliv Rev 2019; 144: 180-9.
[http://dx.doi.org/10.1016/j.addr.2019.06.009] [PMID: 31260712]
[3]
Pathak K, Akhtar N. Nose to brain delivery of nanoformulations for neurotherapeutics in Parkinson’s disease: Defining the preclinical, clinical and toxicity issues. Curr Drug Deliv 2016; 13(8): 1205-21.
[http://dx.doi.org/10.2174/1567201813666160607123409] [PMID: 27280392]
[4]
Gilani SJ, Jahangir MA, Chandrakala J, et al. Nano-based therapy for treatment of skin cancer. Recent Patents Anti-Infect Drug Disc 2018; 13(2): 151-63.
[http://dx.doi.org/10.2174/1574891X13666180911095440] [PMID: 30205801]
[5]
Uppal S, Italiya KS, Chitkara D, Mittal A. Nanoparticulate-based drug delivery systems for small molecule anti-diabetic drugs: An emerging paradigm for effective therapy. Acta Biomater 2018; 81: 20-42.
[http://dx.doi.org/10.1016/j.actbio.2018.09.049] [PMID: 30268916]
[6]
Sunoqrot S, Hamed R, Abdel-Halim H, Tarawneh O. Synergistic interplay of medicinal chemistry and formulation strategies in nanotechnology – from drug discovery to nanocarrier design and development. Curr Top Med Chem 2017; 17(13): 1451-68.
[http://dx.doi.org/10.2174/1568026616666161222111656] [PMID: 28017147]
[7]
Al-Lawati H, Binkhathlan Z, Lavasanifar A. Nanomedicine for the effective and safe delivery of non-steroidal anti-inflammatory drugs: A review of preclinical research. Eur J Pharm Biopharm 2019; 142: 179-94.
[http://dx.doi.org/10.1016/j.ejpb.2019.06.025] [PMID: 31233861]
[8]
Punyamurthula NS, Adelli GR, Gul W, Repka MA, ElSohly MA, Majumdar S. Ocular disposition of Δ8-tetrahydrocannabinol from various topical ophthalmic formulations. AAPS PharmSciTech 2017; 18(6): 1936-45.
[http://dx.doi.org/10.1208/s12249-016-0672-2] [PMID: 27905004]
[9]
Nouar A. Cannabinoid encapsulating nanoparticles for atherosclerosis therapy. An in vitro study (Master's thesis) Delft University of Technology, The Netherlands 2017.
[10]
Conte R, Marturano V, Peluso G, Calarco A, Cerruti P. Recent advances in nanoparticle-mediated delivery of anti-inflammatory phyto-compounds. Int J Mol Sci 2017; 18(4): 709.
[http://dx.doi.org/10.3390/ijms18040709] [PMID: 28350317]
[11]
Grottkau B, Cai X, Wang J, Yang X, Lin Y. Polymeric nanoparticles for a drug delivery system. Curr Drug Metab 2013; 14(8): 840-6.
[http://dx.doi.org/10.2174/138920021131400105] [PMID: 24016112]
[12]
Ngwa W, Kumar R, Moreau M, Dabney R, Herman A. Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids. Front Oncol 2017; 7: 208.
[http://dx.doi.org/10.3389/fonc.2017.00208] [PMID: 28971063]
[13]
Durán-Lobato M, Muñoz-Rubio I, Holgado MÁ, Álvarez-Fuentes J, Fernández-Arévalo M, Martín-Banderas L. Enhanced cellular uptake and biodistribution of a synthetic cannabinoid loaded in surface-modified poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol 2014; 10(6): 1068-79.
[http://dx.doi.org/10.1166/jbn.2014.1806] [PMID: 24749401]
[14]
Martín-Banderas L, Alvarez-Fuentes J, Durán-Lobato M, et al. Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: Formulation, characterization, and cytotoxicity studies. Int J Nanomedicine 2012; 7: 5793-806.
[PMID: 23209365]
[15]
Berrocoso E, Rey-Brea R, Fernández-Arévalo M, Micó JA, Martín-Banderas L. Single oral dose of cannabinoid derivate loaded PLGA nanocarriers relieves neuropathic pain for eleven days. Nanomedicine 2017; 13(8): 2623-32.
[http://dx.doi.org/10.1016/j.nano.2017.07.010] [PMID: 28756090]
[16]
Xian S, Parayath NN, Nehoff H, Giles NM, Greish K. The use of styrene maleic acid nanomicelles encapsulating the synthetic cannabinoid analog WIN55,212-2 for the treatment of cancer. Anticancer Res 2015; 35(9): 4707-12.
[PMID: 26254360]
[17]
Greish K, Mathur A, Al Zahrani R, et al. Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer. J Control Release 2018; 291: 184-95.
[http://dx.doi.org/10.1016/j.jconrel.2018.10.030] [PMID: 30367922]
[18]
Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb AJ, Hoffman A. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. J Control Release 2017; 266: 1-7.
[http://dx.doi.org/10.1016/j.jconrel.2017.09.011] [PMID: 28890215]
[19]
Atsmon J, Cherniakov I, Izgelov D, et al. PTL401, a new formulation based on pro-nano dispersion technology, improves oral cannabinoids bioavailability in healthy volunteers. J Pharm Sci 2018; 107(5): 1423-9.
[http://dx.doi.org/10.1016/j.xphs.2017.12.020] [PMID: 29287930]
[20]
Martín-Banderas L, Muñoz-Rubio I, Prados J, et al. In vitro and in vivo evaluation of Δ9-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy. Int J Pharm 2015; 487(1-2): 205-12.
[http://dx.doi.org/10.1016/j.ijpharm.2015.04.054] [PMID: 25899283]
[21]
Martín-Banderas L, Muñoz-Rubio I, Álvarez-Fuentes J, et al. Engineering of Δ9-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms. Colloids Surf B Biointerfaces 2014; 123: 114-22.
[http://dx.doi.org/10.1016/j.colsurfb.2014.09.002] [PMID: 25262411]
[22]
de la Ossa DHP, Gil-Alegre ME, Ligresti A, et al. Preparation and characterization of Δ9-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines. J Drug Target 2013; 21(8): 710-8.
[http://dx.doi.org/10.3109/1061186X.2013.809089] [PMID: 23773072]
[23]
Hernán Pérez de la Ossa D, Lorente M, Gil-Alegre ME, et al. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PLoS One 2013; 8(1): e54795.
[http://dx.doi.org/10.1371/journal.pone.0054795] [PMID: 23349970]
[24]
Hernán Pérez de la Ossa D, Ligresti A, Gil-Alegre ME, et al. Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy. J Control Release 2012; 161(3): 927-32.
[http://dx.doi.org/10.1016/j.jconrel.2012.05.003] [PMID: 22580111]
[25]
Taskar PS, Patil A, Lakhani P, et al. Δ9-tetrahydrocannabinol derivative-loaded nanoformulation lowers intraocular pressure in normotensive rabbits. Transl Vis Sci Technol 2019; 8(5): 15.
[http://dx.doi.org/10.1167/tvst.8.5.15] [PMID: 31588378]
[26]
Giménez VMM, Díaz-Rodríguez P, Sanz RL, et al. Anandamide-nanoformulation obtained by electrospraying for cardiovascular therapy. Int J Pharm 2019; 566: 1-10.
[http://dx.doi.org/10.1016/j.ijpharm.2019.05.047] [PMID: 31112795]
[27]
Giménez VMM, Russo MG, Narda GE, et al. Synthesis, physicochemical characterisation and biological activity of anandamide/ɛ‐polycaprolactone nanoparticles obtained by electrospraying. IET Nanobiotechnol 2020; 14(1): 86-93.
[http://dx.doi.org/10.1049/iet-nbt.2019.0108] [PMID: 31935683]
[28]
Giménez VMM, Marón MFJ, García S, et al. Central nervous system, peripheral and hemodynamic effects of nanoformulated anandamide in hypertension. Adv Med Sci 2021; 66(1): 72-80.
[http://dx.doi.org/10.1016/j.advms.2020.12.003] [PMID: 33388673]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy